IXICO Awarded Phase II Alzheimer's Disease Study

Share Article

IXICO, Ltd., a global imaging CRO, announced today that a leading pharmaceutical company has awarded IXICO a Phase II clinical imaging study to evaluate the safety and efficacy of their Alzheimer's Disease (AD) therapy with magnetic resonance imaging (MRI).

The integration of our TrialTrackerâ„¢ Image Management System with our internal workflows and core expertise in Alzheimer's Disease allows us to provide an imaging solution unmatched in the industry. We look forward to the successful completion of this study and to our continuing support of this sponsor's AD program.

IXICO, Ltd., a global imaging CRO, announced today that a leading pharmaceutical company has awarded IXICO a Phase II clinical imaging study to evaluate the safety and efficacy of their Alzheimer's Disease (AD) therapy with magnetic resonance imaging (MRI).

IXICO will provide clinical study management and full imaging services, including protocol consultation, site management (site evaluation, qualification, training, and communications), image handling (data transfer and storage via IXICO's TrialTrackerâ„¢ Image Management System), image data QC, real-time reporting, imaging charter development, and analysis of MR images for safety and brain atrophy using a variety of endpoints. The study will commence in autumn 2010, recruiting more than 600 patients at over 60 sites across a four year period.

"This award follows on the heels of our previous success in supporting this sponsor and we are thrilled to take this on as it dovetails nicely with our ongoing efforts on their behalf," said Ciaran Cooper, IXICO's Vice President of Business Development. "This trial further demonstrates our proven abilities in neurodegeneration studies across all clinical trial phases. We have a tremendous track record in AD trials using various modalities, biomarkers, and endpoints, including volumetric MRI assessments of statins, gamma-secretase modulators, and passive immunotherapy monoclonal antibodies."

"We're very pleased with this award," said John Hall, PhD, Director of Business Development. "The integration of our TrialTrackerâ„¢ Image Management System with our internal workflows and core expertise in Alzheimer's Disease allows us to provide an imaging solution unmatched in the industry. We look forward to the successful completion of this study and to our continuing support of this sponsor's AD program."

About IXICO
IXICO, Ltd. is a full-service Imaging CRO that provides comprehensive, technology-based solutions for the pharmaceutical and biotech industries across all therapeutic areas and clinical trials phases. IXICO works within an ISO9001:2008 certified Quality Management System.

For more information please contact: Ciaran Cooper, VP Business Development at ciaran(dot)cooper(at)ixico(dot)com
IXICO, Ltd. The London Bioscience Innovation Centre, 2 Royal College Street,
London NW1 0NH England - http://www.ixico.com
© 2010 IXICO, Ltd. All rights reserved

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Marketing IXICO
Visit website